PolyPid Ltd. (PYPD)
| Market Cap | 127.56M +113.4% |
| Revenue (ttm) | n/a |
| Net Income | -29.80M |
| EPS | -1.35 |
| Shares Out | 20.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 163,121 |
| Open | 6.58 |
| Previous Close | 6.40 |
| Day's Range | 6.03 - 6.58 |
| 52-Week Range | 3.50 - 7.15 |
| Beta | 1.44 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+83.12%) |
| Earnings Date | Nov 11, 2026 |
About PYPD
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral ca... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PYPD stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 83.12% from the latest price.
News
PolyPid price target raised to $8.50 from $8 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan raised the firm’s price target on PolyPid (PYPD) to $8.50 from $8 and keeps a Buy rating on the shares. Ongoing FDA labeling discussions and…
PolyPid Earnings Call Transcript: Q3 2026
D-PLEX100’s FDA review remained on track for the November 28 goal date, with a U.S. launch planned for early 2027, subject to approval. Q3 net loss narrowed to $5.8M; cash was $15.5M, excluding a $15M milestone received in October. European review and pipeline development advanced.
PolyPid Earnings release: Q3 2026
PolyPid released its Q3 2026 earnings on November 11, 2026, summarizing the period's financial results.
PolyPid reports Q3 EPS (24c), consensus 39c
“With our PDUFA goal date fast approaching, this is a defining moment for PolyPid (PYPD),” said Dikla Czaczkes Akselbrad, CEO of PolyPid. “We have a committed partner in Azurity preparing…
PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
D-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing
PolyPid Slides: Investor presentation
PolyPid has posted slides in relation to its latest quarterly earnings report, which was published on November 11, 2026.
PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
PETACH TIKVA, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by ele...
PolyPid Transcript: Investor Day 2026 & KOL Event
D-PLEX100 is nearing a U.S. regulatory decision, with a 2027 launch target and Europe and label expansion as growth avenues. PD01B adds a locally delivered diabetic-foot-infection program, with pre-IND and first-in-human work targeted for H2 2027.
PolyPid Press release: FY 2026
PolyPid issued a press release on October 28, 2026, disclosing material business information to investors.
PolyPid Slides: FY 2026
PolyPid has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 28, 2026.
PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
Company to host virtual Investor Day today at 11:30 AM ET, featuring key opinion leader Warren S. Joseph, DPM, FIDSA All scheduled FDA interactions on track and aligned with D-PLEX ₁₀₀ November 28, 20...
PolyPid rallies after Oppenheimer starts with Outperform rating
As previously reported, Oppenheimer initiated coverage of PolyPid (PYPD) with an Outperform rating and $10 price target The stock in morning trading is up 3% to $5.46. The firm says…
PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
Analysis demonstrates a lower bacterial burden in breakthrough surgical-site infections, with similar proportions of multidrug-resistant organisms between treatment groups Analysis demonstrates a lowe...
PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
Management to outline ‘PolyPid 2030', the Company's long-term vision and pipeline strategy Event to feature Warren S. Joseph, DPM, FIDSA, a nationally recognized specialist in lower extremity infectio...
PolyPid management to meet virtually with Craig-Hallum
Virtual Meeting to be held on October 21 hosted by Craig-Hallum.
European Medicines Agency Validates PolyPid's Marketing Authorization Application for D-PLEX₁₀₀
PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month
PolyPid regains European commercialization rights for D-PLEX
PolyPid (PYPD) announced that PolyPid and ADVANZ PHARMA have mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX in Europe. As a result, the exclusi...
PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities
PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by ele...
PolyPid Transcript: Lytham Partners Fall 2026 Investor Conference
A novel drug platform demonstrated strong phase III results, reducing surgical site infections and outperforming current standards. Commercialization is set for early 2027 through a major partnership, with significant financial milestones and regulatory progress in both the U.S. and Europe.
PolyPid Announces Participation in Upcoming Fall Investor Conferences
PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by el...
PolyPid reports Q2 EPS (35c), consensus (38c)
“The second quarter of 2026 and the first few weeks of the third quarter completed PolyPid’s (PYPD) transition into a commercial-stage company, with the acceptance by the FDA with Priority…
PolyPid Earnings Call Transcript: Q2 2026
FDA accepted NDA for D-PLEX100 with priority review and no review issues, setting a PDUFA date of Nov 28, 2026. Secured a commercialization partnership with Azurity, $30M upfront, and potential for $290M+ in milestones. Cash runway extends into 2028.
PolyPid Earnings release: Q2 2026
PolyPid released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by ele...